Tocris Bioscience™ Adavosertib

Catalog No.	Quantity
75-895-0	50 mg
75-891-0	10 mg

Catalog No. 75-895-0 Supplier Tocris Bioscience™ Supplier No. 7589/50

Description

Potent and selective Wee1 inhibitor

Adavosertib is a potent and selective Wee1 inhibitor (IC50 = 5.2 nM). In a panel of 223 serine/threonine or tyrosine kinases, Adavosertib is highly selective for Wee 1 over all except 8 kinases. In particular Adavosertib shows >100-fold selectivity over human Myt1. Adavosertib blocks CDC2Y15 phosphorylation and Gemcitabine (Cat. No. 3259)-induced DNA damage checkpoint, leading to premature mitotic entry and apoptosis in p53-deficient tumor cell lines. Adavosertib also potentiates the cytotoxic effects of Pemetrexed (Cat. No. 6185), Doxorubicin (Cat. No. 2252), Camptothecin (Cat. No. 1100) and Mitomycin C (Cat. No. 3258) in vitro. Adavosertib synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Specifications

• Chemical Name or Material: 1,2-Dihydro-1-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-(2-propen-1-yl)-3 H-pyrazolo[3,4-d]pyrimidin-3-one
• CAS: 955365-80-7
• Quantity: 50 mg
• Target: Checkpoint Control Kinase Inhibitors
• Molecular Formula: C₂₇H₃₂N₈O₂
• Purity: 98%